Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2020 Jun;86(6):1176-1177.
doi: 10.1111/bcp.14335. Epub 2020 May 7.

COVID-19 and (Hydroxy)chloroquine-Azithromycin Combination: Should We Take the Risk for Our Patients?

Free PMC article

COVID-19 and (Hydroxy)chloroquine-Azithromycin Combination: Should We Take the Risk for Our Patients?

Hervé Javelot et al. Br J Clin Pharmacol. .
Free PMC article


No abstract available

Keywords: COVID-19; QT prolongation; azithromycin; hydroxychloroquine.

Conflict of interest statement

There are no competing interests to declare.

Similar articles

See all similar articles


    1. Yao H, Chen J, Xu YF. Patients with mental health disorders in the COVID‐19 epidemic. Lancet Psychiatry. 2020;7(4):e21. - PMC - PubMed
    1. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID‐19? Int J Antimicrob Agents. 2020;105938. - PMC - PubMed
    1. Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1(5):155‐165. - PMC - PubMed
    1. Woosley RL, Black K, Heise CW, Romero K. what does it offer? Trends Cardiovasc Med. 2018;28(2):94‐99. - PubMed
    1. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc prolongation: systematic review of the evidence. Int J Clin Pharmacol. 2017;39(1):16‐25. - PubMed

LinkOut - more resources